SCHEMBL4570271

SCHEMBL4570271

Nc1nc2nc(Cl)sc2c(=O)[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNP P00491 3/20 0.47
DYRK1A Q13627 2/20 0.46
AURKA O14965 1/20 0.46
DAPK3 O43293 1/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46
NTRK1 P04629 1/20 0.46
PDGFRA P16234 1/20 0.46
PRKACA P17612 1/20 0.46
LTK P29376 1/20 0.46
GRK5 P34947 1/20 0.46
MAPK8 P45983 1/20 0.46
CSNK1A1 P48729 1/20 0.46
CDK8 P49336 1/20 0.46
CLK2 P49760 1/20 0.46
CDK7 P50613 1/20 0.46
CDK9 P50750 1/20 0.46
PRKX P51817 1/20 0.46
NEK2 P51955 1/20 0.46
LIMK1 P53667 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thiazolopyrimidine SCHEMBL1703410 0.81 RPS6KA3 (0.52) PNPTHRBMITFTP53ALOX15
SCHEMBL8435574 0.78 PNP (0.47) PNPTHRBMITFTP53ALOX15
SCHEMBL9151696 0.67 KDM4E (0.50) PNPTHRBMITFTP53ALOX15
SCHEMBL8664722 0.65 RPS6KA3 (0.61) DYRK1AAURKADAPK3PRKD3MAP4K4
SCHEMBL20577 0.65 PNP (0.73) PNPTHRBMAPTKDM4EMEN1
SCHEMBL338384 0.65 RPS6KA3 (0.52) PNPDYRK1ATHRBMITFTP53
SCHEMBL8437718 0.65 CXCR1 (0.45) PNPDYRK1ACLK2CDK9LIMK1
8-Aminoguanine SCHEMBL21761 0.65 PNP (1.00) PNPTHRBMITFTP53ALOX15
SCHEMBL13022826 0.63 PNP (0.46) PNPDYRK1ATHRBMITFTP53
SCHEMBL6975489 0.63 RPS6KA3 (0.49) PNPDYRK1ATHRBMITFTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9993491-B2 Guanine riboswitch binding compounds and their use as antibiotics SOCPRA—SCIENCES ET GÉNIE S.E.C. (CA) 2018-06-12 US disclosed
US-9993491-B2 Guanine riboswitch binding compounds and their use as antibiotics SOCPRA—SCIENCES ET GÉNIE S.E.C. (CA) 2018-06-12 US disclosed
EP-2440533-B1 GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS SOCPRA SCIENCES ET GÉNIE S E C (CA) 2015-09-23 EP disclosed
US-20150150890-A1 GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS UNIVERSITE DE SHERBROOKE (CA) 2015-06-04 US disclosed
US-20150150890-A1 GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS UNIVERSITE DE SHERBROOKE (CA) 2015-06-04 US disclosed
US-20120122819-A1 GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS SOCPRA - SCIENCES ET GENIE S.E.C. (CA) 2012-05-17 US disclosed
US-20120122819-A1 GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS SOCPRA - SCIENCES ET GENIE S.E.C. (CA) 2012-05-17 US disclosed
WO-2010142027-A1 GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS SOCPRA - SCIENCES ET GENIE S. E. C. (CA) 2010-12-16 WO disclosed
EP-0636372-B1 Antiviral, antitumor, antimetastatic, immune system enhancing 7-thia-guanosine derivatives ICN PHARMACEUTICALS (US) 1998-12-02 EP disclosed
EP-0348446-B1 ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES UNIV BRIGHAM YOUNG (US) 1995-08-09 EP disclosed
EP-0636372-A1 Antiviral, antitumor, antimetastatic, immune system enhancing 7-thia-guanosine derivatives BRIGHAM YOUNG UNIVERSITY (US) 1995-02-01 EP disclosed
EP-0348446-A4 ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES 1991-09-25 EP disclosed
US-5041426-A Viricides, antitumor agents BRIGHAM YOUNG UNIVERSITY (US) 1991-08-20 US disclosed
EP-0348446-A1 ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES. UNIV BRIGHAM YOUNG (US) 1990-01-03 EP disclosed
US-4880784-A ANTITUMOR AGENTS BRIGHAM YOUNG UNIVERSITY (US) 1989-11-14 US disclosed
WO-1989005649-A1 ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES BRIGHAM YOUNG UNIVERSITY (US) 1989-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150150890-A1 GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS GDA, RNMT, GNPDA1 PNP 618/4885DYRK1A 3837/4885AURKA 4450/4885
US-20120122819-A1 GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS GDA, RNMT, GNPDA1 PNP 618/4885DYRK1A 3837/4885AURKA 4450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.